ACTG 260: a Randomized, Phase I-II, Dose-Ranging Trial of the Anti-Human Immunodeficiency Virus Activity of Delavirdine Monotherapy

ACTG 260 was an open-label, four-arm trial designed to study the safety and anti-human immunodeficiency virus (anti-HIV) activity of delavirdine monotherapy at three ranges of concentrations in plasma compared to those of control therapy with zidovudine or didanosine. Delavirdine doses were adjusted...

Descripció completa

Dades bibliogràfiques

Publicat a:	Antimicrob Agents Chemother
Autors principals:	Para, Michael F., Meehan, Patricia, Holden-Wiltse, Jeanne, Fischl, Margaret, Morse, Gene, Shafer, Robert, Demeter, Lisa M., Wood, Kenneth, Nevin, Tom, Virani-Ketter, Nzeera, Freimuth, William W.
Format:	Artigo
Idioma:	Inglês
Publicat:	American Society for Microbiology (ASM) 1999
Matèries:	Antiviral Agents
Accés en línia:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC89281/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/10348755/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.43.6.1373
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!